Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized single-blind pharmacokinetic and safety study of sotatercept dosing by body weight versus weight-banded dosing in pulmonary arterial hypertension
MOH_2024-10-07_013683Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sotatercept in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Merck & Co. Primary endpoint: Pharmacokinetics of sotatercept. Started Oct 2024; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2024-10-07_013683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-07_013683.